{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:44:11Z","timestamp":1775864651907,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s00415-006-0320-z","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T09:21:51Z","timestamp":1168507311000},"page":"1633-1639","source":"Crossref","is-referenced-by-count":22,"title":["End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson\u2019s disease"],"prefix":"10.1007","volume":"253","author":[{"given":"Astrid","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Di","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Varanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Anzellotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"D\u2019Andreagiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Stocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Onofrj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl 1","key":"320_CR1","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00019052-200312001-00004","volume":"16","author":"U Bonuccelli","year":"2003","unstructured":"Bonuccelli U (2003) Comparing dopamine agonists in Parkinson\u2019s disease. Curr Opin Neurol 16(Suppl 1):S13\u20139","journal-title":"Curr Opin Neurol"},{"key":"320_CR2","first-page":"335","volume":"86","author":"TN Chase","year":"2001","unstructured":"Chase TN, Konitsiotis S, Oh JD (2001) Striatal molecular mechanisms and motor dysfunction in Parkinson\u2019s Disease. Adv Neurol 86:335\u201360","journal-title":"Adv Neurol"},{"key":"320_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00002826-200305000-00008","volume":"26","author":"S Cristina","year":"2003","unstructured":"Cristina S, Zangalia R, Mancini F, Martignoni E, Nappi G, Pacchetti C (2003) High-dose ropinirole in advanced Parkinson\u2019s disease with severe dyskinesias. Clin Neuropharmacol 26:146\u201350","journal-title":"Clin Neuropharmacol"},{"key":"320_CR4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/brain\/awh102","volume":"4","author":"R la Fuente-Fern\u00e1ndez de","year":"2004","unstructured":"de la Fuente-Fern\u00e1ndez R , Schulzer M, Mak E, Calne DB, Stoessl AJ (2004) Presynaptic mechanisms of motor fluctuations in Parkinson\u2019s disease: a probabilistic model. Brain 4:888\u201399","journal-title":"Brain"},{"key":"320_CR5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","volume":"41","author":"D Deleu","year":"2002","unstructured":"Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease. Clin Pharmacokinet 41:261\u2013309","journal-title":"Clin Pharmacokinet"},{"key":"320_CR6","unstructured":"Deutsche Gesellschaft f\u0171r Neurologie:Leitlinien-Parkinson-Syndrome; 4.3.1.1. Therapieeinleitung http:\/\/www.dgn.org\/168.0htlm#926"},{"key":"320_CR7","unstructured":"Fahn S, Elton R, Members of UPDRS Development Committee (1987) In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds). Recent Developments in Parkinson\u2019s Disease, Vol 2. Macmillan Health Care Information, Florham Park NJ, pp 153\u201364"},{"key":"320_CR8","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u2013508","journal-title":"N Engl J Med"},{"key":"320_CR9","first-page":"324","volume":"52","author":"H Fukuyama","year":"1996","unstructured":"Fukuyama H, Kawamura J, Akiguchi I, Kimura J, Imai T (1996) Bromocriptine therapy in early stage Parkinson\u2019s Disease. Eur Neurol 52:324\u20138","journal-title":"Eur Neurol"},{"key":"320_CR10","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/mds.10504","volume":"18","author":"CG Goetz","year":"2003","unstructured":"Goetz CG, Janko K, Blasucci L, Jaglin JA (2003) Impact of placebo assignment in clinical trials of Parkinson\u2019s Disease. Mov Disord 18:1146\u20139","journal-title":"Mov Disord"},{"key":"320_CR11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","volume":"20","author":"CG Goetz","year":"2005","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson\u2019s disease: 2001 to 2004. Mov Disord 20:523\u201339","journal-title":"Mov Disord"},{"key":"320_CR12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp.52.3.324","volume":"52","author":"MA Hely","year":"1989","unstructured":"Hely MA, Morris JG, Rail D, Reid WG, O\u2019Sullivan DJ, Williamson PM, Genge S, Broe GA (1989) The Sydney Multicentre Study of Parkinson\u2019s disease: a report on the first 3\u00a0years. J Neurol Neurosurg Psychiatry 52:324\u20138","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"320_CR13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427\u201342","journal-title":"Neurology"},{"key":"320_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u20134","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"320_CR15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","volume":"20","author":"R Inzelberg","year":"2003","unstructured":"Inzelberg R, Schechtman E, Nisipeanu P (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson\u2019s disease: an evidence-based comparison. Drugs Aging 20:847\u201355","journal-title":"Drugs Aging"},{"issue":"Suppl 11","key":"320_CR16","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson\u2019s disease: Clinical manifestations. Mov Disord 20(Suppl 11):S11\u20136","journal-title":"Mov Disord"},{"key":"320_CR17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.58.suppl_1.S1","volume":"58","author":"P Jenner","year":"2002","unstructured":"Jenner P (2002) Pharmacology of dopamineagonists in the treatment of Parkinson\u2019s Disease. Neurology 58:S1\u2013S8","journal-title":"Neurology"},{"issue":"suppl3","key":"320_CR18","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.61.6_suppl_3.S4","volume":"61","author":"P Jenner","year":"2003","unstructured":"Jenner P (2003) The MPTP-treated primate as a model of motor complications. Neurology 61(suppl3):S4\u2013S11","journal-title":"Neurology"},{"key":"320_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","volume":"39","author":"CM Kaye","year":"2000","unstructured":"Kaye CM, Nicholls B (2000) Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39:243\u201354","journal-title":"Clin Pharmacokinet"},{"key":"320_CR20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0404.2002.01343.x","volume":"106","author":"AD Korczyn","year":"2002","unstructured":"Korczyn AD, Thalamas C, Adler CH (2002) Dosing with ropinirole in a clinical setting. Acta Neurol Scand 106:200\u20134","journal-title":"Acta Neurol Scand"},{"key":"320_CR21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.57.9.1687","volume":"57","author":"AJ Lees","year":"2001","unstructured":"Lees AJ (2001) Ten-years follow-up of three different initial treatments in de-novo PD. A randomized trial. Neurology 57:1687\u20131694","journal-title":"Neurology"},{"key":"320_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2004.10.002","volume":"11","author":"L Mazzella","year":"2005","unstructured":"Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A (2005) Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson\u2019s disease on l-dopa monotherapy. Parkinsonism Relat Disord 11:151\u20135","journal-title":"Parkinsonism Relat Disord"},{"key":"320_CR23","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","volume":"285","author":"D Moher","year":"2001","unstructured":"Moher D, Schulze KF, Altman D for the CONSORT group (2001) The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. JAMA 285:1987\u201391","journal-title":"JAMA"},{"key":"320_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","volume":"21","author":"WH Oertel","year":"2006","unstructured":"Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J (2006) Pergolide versus levodopa monotherapy in early Parkinson\u2019s disease patients: The PELMOPET study. Mov Disord 21:343\u201353","journal-title":"Mov Disord"},{"key":"320_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000050749","volume":"46","author":"M Onofrj","year":"2001","unstructured":"Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L (2001) Switch-over from Tolcapone to Entacapone in severe Parkinson\u2019s Disease patients. Eur Neurol 46:11\u20136","journal-title":"Eur Neurol"},{"key":"320_CR26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002826-200001000-00007","volume":"23","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson\u2019s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23:34\u201344","journal-title":"Clin Neuropharmacol"},{"key":"320_CR27","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653\u20131661","journal-title":"JAMA"},{"issue":"suppl 2","key":"320_CR28","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/WNL.51.2_Suppl_2.S25","volume":"51","author":"NP Quinn","year":"1998","unstructured":"Quinn NP (1998) Classification of fluctuations in patients with Parkinson\u2019s Disease. Neurology 51(suppl 2):S25\u2013S29","journal-title":"Neurology"},{"key":"320_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13","author":"O Rascol","year":"1998","unstructured":"Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F (1998) Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 13:39\u201345","journal-title":"Mov Disord"},{"issue":"20","key":"320_CR30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484\u201391","journal-title":"N Engl J Med"},{"issue":"3","key":"320_CR31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","volume":"49","author":"KM Shannon","year":"1997","unstructured":"Shannon KM, Bennett JP, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson\u2019s disease. The Pramipexole Study Group. Neurology 49(3):724\u20138","journal-title":"Neurology"},{"issue":"4","key":"320_CR32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D","volume":"15","author":"LM Shulman","year":"2000","unstructured":"Shulman LM, Minager A, Rabinstein A, Weiner WJ (2000) The use of dopamine agonists in very elderly patients with Parkinson\u2019s disease. Mov Disord 15(4):664\u20138","journal-title":"Mov Disord"},{"issue":"8","key":"320_CR33","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.10465","volume":"18","author":"AM Smala","year":"2003","unstructured":"Smala AM, Spottke EA, Machat O, Siebert U, Meyer D, Kohne-Volland R, Reuther M, DuChane J, Oertel WH, Berger KB, Dodel RC (2003) Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord 18(8):898\u2013905","journal-title":"Mov Disord"},{"issue":"2","key":"320_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mds.1070","volume":"16","author":"F Stocchi","year":"2001","unstructured":"Stocchi F, Vacca L, Berardelli A, De Pandis F, Ruggieri S (2001) Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov Disord 16(2):301\u20135","journal-title":"Mov Disord"},{"issue":"7","key":"320_CR35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00415-003-1086-0","volume":"250","author":"F Stocchi","year":"2003","unstructured":"Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S (2003) Dual dopamine agonist treatment in Parkinson\u2019s disease. J Neurol 250(7):822\u2013826","journal-title":"J Neurol"},{"key":"320_CR36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00002826-200109000-00001","volume":"24","author":"EK Tan","year":"2001","unstructured":"Tan EK, Jankovic J (2001) Choosing dopamine agonists in Parkinson\u2019s disease. Clin Neuropharmacol 24:247\u201353","journal-title":"Clin Neuropharmacol"},{"key":"320_CR37","first-page":"141","volume":"75","author":"A Thomas","year":"2004","unstructured":"Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 75:141\u20133","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"320_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessel AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) REAL-PET Study Group. Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93\u2013101","journal-title":"Ann Neurol"},{"key":"320_CR39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","volume":"277","author":"World","year":"1997","unstructured":"World Medical Association (1997) Declaration of Helsinki. Recommendations Guiding Physicians in Biomedical Research involving human subjects. JAMA 277:925\u20136","journal-title":"JAMA"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-0320-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-006-0320-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-0320-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:04:11Z","timestamp":1559070251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-006-0320-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s00415-006-0320-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}